A review of recent filings with the Securities and Exchange Commission reveals that Luke Evnin, a director at Werewolf Therapeutics, Inc. (NASDAQ:HOWL), completed several sales of common stock amounting to $66,200 over three consecutive business days. These transactions occurred between May 27 and May 29, 2026, with the share price fluctuating within a narrow band ranging from $0.45 to $0.48.
Crucially, these divestitures were not spontaneous; they were executed in adherence to a Rule 10b5-1 trading plan that Mr. Evnin originally established on March 26, 2026. The nature of the sales suggests pre-meditated financial action by an insider.
The timing of these insider transactions warrants attention given the current market performance of HOWL. Shares are currently trading near their 52-week low of $0.40, a figure that reflects a substantial decrease of approximately 65% over the last twelve months. Despite this marked decline in share price, available InvestingPro analysis provides counterpoints suggesting potential underlying value. Specifically, the platform assigns a Fair Value of $0.53 to the stock, implying possible upside from current trading levels.
The company's total market capitalization has been reported as having shrunk to $21.87 million, further highlighting the recent financial contraction experienced by Werewolf Therapeutics.
The sales were structured across three distinct dates, with specific details available for each transaction:
- May 27: Mr. Evnin disposed of 80,852 shares of common stock through various holdings. The weighted average price for this day was $0.48 per share, although individual sale prices ranged from $0.46 to $0.49705. Following the completion of this sale, the indirect common stock holdings totaled 682,833 shares.
- May 28: A subsequent transaction involved the selling of 27,698 shares at a weighted average price of $0.46 per share. The prices for these specific shares varied between $0.455 and $0.4858. After this day's sales, the indirect ownership level dropped to 655,135 shares.
- May 29: The final reported sale date saw the divestment of 32,556 shares, which were transacted at a weighted average price of $0.45 per share. Individual prices for these sales ranged from $0.44 to $0.4557. This concluding action reduced the total indirect shares held to 622,579.
Beyond the specific transactions, various market indicators provide additional context on HOWL's current status. According to InvestingPro Tips, the stock's Relative Strength Index (RSI) suggests that it is currently in oversold territory. Furthermore, data indicates that shares have declined 55% over the past six months. Investors seeking deeper insight into the biotech company’s financial standing and market positioning can access additional ProTips through the platform.
It must be noted that these shares are held indirectly by Mr. Evnin through multiple entities, including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Mr. Evnin is listed as a member or manager of the general partners or managers for these entities and explicitly disclaims beneficial ownership of the securities except to the extent of his personal pecuniary interest therein.
For readers interested in evaluating potential value, valuation metrics are available through tools like the Fair Value calculator, which utilizes a combination of 17 proven industry valuation models to determine accuracy. This tool allows for identifying undervalued stocks and assessing potential upside across various market segments.